Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Møller Pedersen

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Blood|November 16, 2007
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 studyBertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneTina Marie Green, Ken H Young, Carlo Visco, et al.
Oncoimmunology|January 9, 2018
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapyShamaila Munir Ahmad, Evelina Martinenaite, Morten Holmström, et al.
British Journal of Haematology|April 23, 2010
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 studyBertrand Coiffier, Nedjad Losic, Birgitte Biilmann Rønn, et al.
Plos One|March 15, 2014
Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphomaMinna Taskinen, Riku Louhimo, Satu Koivula, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
Blood Advances|November 21, 2024
Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort studyElisabeth Reuben Tolley, Torsten Holm Nielsen, Ditte Stampe Hersby, et al.
Trials|July 19, 2012
The FIB-PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trialAnne Juul Wikkelsoe, Arash Afshari, Jakob Stensballe, et al.
European Journal of Haematology|January 9, 2025
Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real-World SettingTine Litske Bennedsen, Mikkel Runason Simonsen, Paw Jensen, et al.
Frontiers in Oncology|December 9, 2022
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHVUffe Klausen, Jacob Handlos Grauslund, Nicolai Grønne Dahlager Jørgensen, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Blood|November 16, 2007
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 studyBertrand Coiffier, Stéphane Lepretre, Lars Møller Pedersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2012
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneTina Marie Green, Ken H Young, Carlo Visco, et al.
Oncoimmunology|January 9, 2018
The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapyShamaila Munir Ahmad, Evelina Martinenaite, Morten Holmström, et al.
British Journal of Haematology|April 23, 2010
Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 studyBertrand Coiffier, Nedjad Losic, Birgitte Biilmann Rønn, et al.
Plos One|March 15, 2014
Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphomaMinna Taskinen, Riku Louhimo, Satu Koivula, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
Blood Advances|November 21, 2024
Incidence and characterization of secondary CNS lymphoma in 1972 patients with DLBCL: a Danish nationwide cohort studyElisabeth Reuben Tolley, Torsten Holm Nielsen, Ditte Stampe Hersby, et al.
Trials|July 19, 2012
The FIB-PPH trial: fibrinogen concentrate as initial treatment for postpartum haemorrhage: study protocol for a randomised controlled trialAnne Juul Wikkelsoe, Arash Afshari, Jakob Stensballe, et al.
European Journal of Haematology|January 9, 2025
Impact of Trial Eligibility Criteria on Outcomes of 1183 Patients With Follicular Lymphoma Treated in the Real-World SettingTine Litske Bennedsen, Mikkel Runason Simonsen, Paw Jensen, et al.
Frontiers in Oncology|December 9, 2022
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHVUffe Klausen, Jacob Handlos Grauslund, Nicolai Grønne Dahlager Jørgensen, et al.
Pageof 5